Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2001 Jul;94(7):369-70.
doi: 10.1177/014107680109400726.

Diabetic nephropathy and dyslipidaemia

A Afaq
Comment

Diabetic nephropathy and dyslipidaemia

A Afaq. J R Soc Med. 2001 Jul.
No abstract available

PubMed Disclaimer

Comment on

  • Management of diabetic nephropathy.
    Foggensteiner L, Mulroy S, Firth J. Foggensteiner L, et al. J R Soc Med. 2001 May;94(5):210-7. doi: 10.1177/014107680109400504. J R Soc Med. 2001. PMID: 11385086 Free PMC article. Review. No abstract available.

References

    1. Jandeleit-Dahm K, Cao Z, Cox AJ, et al. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int 1999;71(suppl): S31-6 - PubMed
    1. Inman SR, Stowe NT, Cressman MD, et al. Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999;317: 215-21 - PubMed
    1. Yukawa S, Mune M, Yamada Y, Otani H, Kishino M, Tone Y. Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Kidney Int 1999;71(suppl): S141-3 - PubMed
    1. Lam KS, Cheng JK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38: 604-9 - PubMed
    1. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59: 260-9 - PubMed

MeSH terms

Substances